Published: 20 September 2020
Authors: Limin Deng Ruilin Quan Yuanhua Yang Zhenwen Yang Hongyan Tian Shengqing Li Jieyan Shen Yingqun Ji Gangcheng Zhang Caojin Zhang Guangyi Wang Yuhao Liu Zhaozhong Cheng Zaixin Yu Zhiyuan Song Zeqi Zheng Wei Cui Yucheng Chen Shuang Liu Changming Xiong Guangliang Shan Jianguo He
Source: This abstract has been sourced from NZ Respiratory Research Review Issue 183
The purpose of this study was to report the characteristics and long‐term survival of patients with CTEPH treated in three distinct ways: PEA, BPA and medical therapy.
Patients diagnosed with CTEPH were included in the registry that was set up in 18 centres from August 2009 to July 2018. The characteristics and survival of patients with CTEPH receiving the different treatments were reported. Prognostic factors were evaluated by Cox regression model.
A total of 593 patients with CTEPH were included. Eighty‐one patients were treated with PEA, 61 with BPA and 451 with drugs. The estimated survival rates at 1, 3, 5 and 8 years were, respectively, 95.2%, 84.6%, 73.4% and 66.6% in all patients; 92.6%, 89.6%, 87.5% and 80.2% in surgical patients; and 95.4%, 88.3%, 71.0% and 64.1% in medically treated patients. The estimated survival rates at 1, 3, 5 and 7 years in patients treated with BPA were 96.7%, 88.1%, 70.0% and 70.0%, respectively. For all patients, PEA was an independent predictor of survival. Other independent risk factors were CHD, cardiac index, PVR, big endothelin‐1, APE and 6MWD.
This is the first multicentre prospective registry reporting baseline characteristics and estimated survival of patients with CTEPH in China. The long‐term survival rates are similar to those of patients in the international and Spanish registries. PEA is an independent predictor of survival.
